TY - JOUR
T1 - Problem solving to improve adherence and asthma outcomes in urban adults with moderate or severe asthma
T2 - A randomized controlled trial
AU - Apter, Andrea J.
AU - Wang, Xingmei
AU - Bogen, Daniel K.
AU - Rand, Cynthia S
AU - McElligott, Sean
AU - Polsky, Daniel
AU - Gonzalez, Rodalyn
AU - Priolo, Chantel
AU - Adam, Bariituu
AU - Geer, Sabrina
AU - Ten Have, Thomas
N1 - Funding Information:
Supported by National Institutes of Health grants HL070392 and HL088469 . A.J.A. was supported by HL070392, HL088469, and HL099612. X.W., D.K.B., T.T.H., R.G., C.P., B.A., and S.G. were supported by HL070392 and HL099612. D.P. was supported by HL070392.
Funding Information:
Disclosure of potential conflict of interest: A. J. Apter receives research support from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) and Astra Zeneca/Bristol-Myers Squibb . D. K. Bogen receives research support from the NIH/NHLBI . C. S. Rand is on the advisory board for the Merck Foundation/MCAN and has consultant arrangements with TEVA. D. Polsky has consultant arrangements with GlaxoSmithKline. The rest of the authors have declared that they have no conflict of interest.
PY - 2011/9
Y1 - 2011/9
N2 - Background: Improving inhaled corticosteroid (ICS) adherence should improve asthma outcomes. Objective: In a randomized controlled trial we tested whether an individualized problem-solving (PS) intervention improves ICS adherence and asthma outcomes. Methods: Adults with moderate or severe asthma from clinics serving urban neighborhoods were randomized to PS (ie, defining specific barriers to adherence, proposing/weighing solutions, trying the best, assessing, and revising) or standard asthma education (AE) for 3 months and then observed for 3 months. Adherence was monitored electronically. Outcomes included the following: asthma control, FEV1, asthma-related quality of life, emergency department (ED) visits, and hospitalizations. In an intention-to-treat-analysis longitudinal models using random effects and regression were used. Results: Three hundred thirty-three adults were randomized: 49 ± 14 years of age, 72% female, 68% African American, 7% Latino, mean FEV1 of 66% ± 19%, and 103 (31%) with hospitalizations and 172 (52%) with ED visits for asthma in the prior year. There was no difference between groups in overall change in any outcome (P >.20). Mean adherence (61% ± 27%) decreased significantly (P =.0004) over time by 14% and 10% in the AE and PS groups, respectively. Asthma control improved overall by 15% (P =.002). In both groups FEV1 and quality of life improved by 6% (P =.01) and 18% (P <.0001), respectively. However, the improvement in FEV1 only occurred during monitoring but not subsequently after randomization. Rates of ED visits and hospitalizations did not significantly decrease over the study period. Conclusion: PS was not better than AE in improving adherence or asthma outcomes. However, monitoring ICS use with provision of medications and attention, which was imposed on both groups, was associated with improvement in FEV1 and asthma control.
AB - Background: Improving inhaled corticosteroid (ICS) adherence should improve asthma outcomes. Objective: In a randomized controlled trial we tested whether an individualized problem-solving (PS) intervention improves ICS adherence and asthma outcomes. Methods: Adults with moderate or severe asthma from clinics serving urban neighborhoods were randomized to PS (ie, defining specific barriers to adherence, proposing/weighing solutions, trying the best, assessing, and revising) or standard asthma education (AE) for 3 months and then observed for 3 months. Adherence was monitored electronically. Outcomes included the following: asthma control, FEV1, asthma-related quality of life, emergency department (ED) visits, and hospitalizations. In an intention-to-treat-analysis longitudinal models using random effects and regression were used. Results: Three hundred thirty-three adults were randomized: 49 ± 14 years of age, 72% female, 68% African American, 7% Latino, mean FEV1 of 66% ± 19%, and 103 (31%) with hospitalizations and 172 (52%) with ED visits for asthma in the prior year. There was no difference between groups in overall change in any outcome (P >.20). Mean adherence (61% ± 27%) decreased significantly (P =.0004) over time by 14% and 10% in the AE and PS groups, respectively. Asthma control improved overall by 15% (P =.002). In both groups FEV1 and quality of life improved by 6% (P =.01) and 18% (P <.0001), respectively. However, the improvement in FEV1 only occurred during monitoring but not subsequently after randomization. Rates of ED visits and hospitalizations did not significantly decrease over the study period. Conclusion: PS was not better than AE in improving adherence or asthma outcomes. However, monitoring ICS use with provision of medications and attention, which was imposed on both groups, was associated with improvement in FEV1 and asthma control.
KW - Asthma
KW - adherence
KW - adults
KW - health disparities
KW - inhaled corticosteroids
KW - inner-city asthma
KW - problem solving
UR - http://www.scopus.com/inward/record.url?scp=80052266989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052266989&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2011.05.010
DO - 10.1016/j.jaci.2011.05.010
M3 - Article
C2 - 21704360
AN - SCOPUS:80052266989
SN - 0091-6749
VL - 128
SP - 516-523.e5
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 3
ER -